Clinical trials
Arthritis, Juvenile clinical trials
Below are recruiting arthritis, juvenile clinical trials, each written for real people, not researchers. We’re tracking 56 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT06474546Recruiting
Diet intervention feasibility study for juvenile arthritis
This trial tests whether a special diet can help children and teens with juvenile arthritis. If you join, you will follow the diet and provide stool samples so the researchers can see how it affects your gut and arthritis.
Winnipeg, ManitobaAges 8–18 - NCT06668181RecruitingPhase 3
Study of bimekizumab for kids with certain types of juvenile arthritis
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
CalgaryAges 2–18 - NCT06718569Recruiting
Pain in Inflammatory Joint Diseases
This study looks at pain in people with inflammatory joint diseases. It aims to understand how pain changes when you start or switch to a newer type of arthritis medication.
OsloAges 18 years+ - NCT07217782Recruiting
Pain in Juvenile Arthritis Study
This study looks at pain in kids with juvenile arthritis compared to healthy kids. It may help researchers understand pain better and improve future treatments.
St Louis, MissouriAges 9–17 - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT03773965RecruitingPhase 3
Baricitinib study for kids with juvenile arthritis
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
RosarioAges 1–18 - NCT05534347Recruiting
Blood marker study in teens with juvenile arthritis
This study looks at blood (and related) markers that may reflect inflammation in people with juvenile idiopathic arthritis. It may help doctors better understand disease activity and guide future care for patients who are able to join.
Paris, IDFAges 16 years+ - NCT06007456Recruiting
Study of Juvenile Idiopathic Arthritis in Children
This study looks at children with arthritis to better understand their condition using clinical exams, lab tests, and ultrasounds. It may help doctors learn more about different types of juvenile arthritis.
TriesteAges Up to 18 years - NCT06806774Recruiting
Daily living test for children with juvenile arthritis
This study tests whether a simple daily activities test works well for children and teens with juvenile idiopathic arthritis. It may help doctors better understand how the condition affects everyday tasks.
AnkaraAges 8–18 - NCT06869551RecruitingPhase 3
Testing a New Drug for Juvenile Psoriatic Arthritis
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
Lancaster, CaliforniaAges 5–17 - NCT06874608Recruiting
Does an exclusion diet help juvenile arthritis?
This study tests if removing certain foods can improve arthritis symptoms in children aged 6 to 17. It may be an option if current medicines are not working well or if you want to explore dietary changes.
FlorenceAges 6–18 - NCT07234747Recruiting
Core stability: exergaming vs. standard exercises for kids with JIA
This study compares two types of core-strengthening exercises for children with juvenile idiopathic arthritis (JIA). One group does standard core-stability exercises, and the other plays active video games (exergaming) that work the same muscles. The goal is to see which approach works better and is more fun for kids.
Istanbul, BuyukcekmeceAges 8–12 - NCT07517575RecruitingPhase 2
Olokizumab for Children with Juvenile Idiopathic Arthritis
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
Kazan'Ages 2–17 - NCT07386587Enrolling by invitationPhase 3
Methotrexate plus etanercept for juvenile arthritis
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
Lahore, Punjab ProvinceAges 2–16 - NCT06751238RecruitingPhase 1
Secukinumab for children with psoriatic arthritis
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
Loma Linda, CaliforniaAges 2–17 - NCT02991469RecruitingPhase 2
Testing sarilumab for children with systemic juvenile arthritis
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
San Miguel de Tucumán, Tucumán ProvinceAges 1–17 - NCT03245801Recruiting
Juvenile arthritis registry for newly diagnosed children
This study collects information about children with juvenile idiopathic arthritis (JIA) soon after diagnosis. The information helps researchers understand how the condition and treatments change over time, and it may guide future care.
Calgary, AlbertaAges Up to 18 years - NCT04804553RecruitingPhase 3
Apremilast for children with active juvenile psoriatic arthritis
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
BregenzAges 5–17 - NCT06463379RecruitingPhase 3
Intravenous pulse therapy for tough juvenile arthritis
This trial tests whether a type of intravenous medicine (called pulse therapy) can help children with arthritis that hasn't improved after other treatments. It aims to bring the disease into remission.
CairoAges 2–18 - NCT01962415RecruitingPhase 2
Reduced-intensity stem cell transplant for non-cancer disorders
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
Pittsburgh, PennsylvaniaAges 2 months–55 years - NCT05925452Recruiting
Genalumab for children with active systemic juvenile arthritis
This trial studies whether a medicine called genalumab can reduce inflammation and improve symptoms in children with active systemic juvenile idiopathic arthritis (sJIA). It also checks how safe the treatment is, including possible side effects.
Beijing, BenjingAges 2–17 - NCT06654882RecruitingPhase 3
Switching medications after first treatment fails in juvenile arthritis
This study tests different medication sequences for children and teens with polyarticular juvenile idiopathic arthritis (JIA) who still have moderate or high disease activity after at least 3 months on their first tumor necrosis factor inhibitor (TNFi) therapy. The goal is to find the best next step to control symptoms and improve quality of life.
San Francisco, CaliforniaAges 2–17 - NCT05767047RecruitingPhase 3
Apremilast study for children with mouth ulcers from Behçet’s
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
ThessalonikiAges 5–18
Hear when a new Arthritis, Juvenile trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for arthritis, juvenile?
- Yes. Clin2 currently lists 56 recruiting arthritis, juvenile studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a arthritis, juvenile trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a arthritis, juvenile trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.